Lupin receives Form 483 and three observations from USFDA for New Jersey facility

Lupin said the US drug regulator issued the same after concluding its inspection, which was conducted from April 13 to April 17, 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *